^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion–Positive Metastatic Urothelial Carcinoma
Excerpt:
...patient’s primary tumor, which showed an FGFR3-TACC3 fusion involving intron 17 of FGFR3 and intron 10 of TACC3….the patient was treated with atezolizumab, and subsequent CAP CT showed a CR. On the basis of the patient’s remarkable response and unclear value of indefinite therapy, atezolizumab was discontinued in October 2017, and the patient continues to be in CR 6 months later.
DOI:
10.1200/PO.18.00117
